---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-080081"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:25:15.776906+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma CFO resigns; reports FY2021 Jelmyto revenue $48M, net loss $110.8M

## Summary
- CFO Molly Henderson resigns effective March 25, 2022; replaced by Dong Kim (VP Finance).
- FY2021 Jelmyto net product revenue $48.0M, up 307% YoY; Q4 revenue $16.2M, up 42% QoQ.
- FY2021 net loss $110.8M ($4.96/share) vs $128.5M loss in prior year.
- 2022 revenue guidance $70-80M; operating expenses guided $140-160M; RTW financing expense $22-26M.
- Closed $75M tranche of up to $100M senior secured term loan facility with Pharmakon Advisors.

## SEC filing metadata
- accession: 0001193125-22-080081
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/0001193125-22-080081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/d258593d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-080081
- JSON: https://secwatch.observer/filing/0001193125-22-080081.json
- Plain text: https://secwatch.observer/filing/0001193125-22-080081.txt

## Key facts
- Executive change
  Dong (Don) Kim was appointed as Chief Financial Officer at UroGen Pharma Ltd..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective as of March 25, 2022 (the “Effective Date”), the Company appointed Dong (Don) Kim as Chief Financial Officer of the Company, as well as the Company’s principal financial officer and principal accounting officer, replacing Ms. Henderson in such capacities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/0001193125-22-080081-index.htm
- Executive change
  Molly Henderson resigned as Chief Financial Officer at UroGen Pharma Ltd..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On March 17, 2022, Molly Henderson tendered her resignation as the Company’s Chief Financial Officer, effective March 25, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/0001193125-22-080081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.